TAKE working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

0.00×	0.00×	—	11.74×	3.13×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.73×	0.73×	—	103.16×	57.99×
9.35×	9.35×	—	306.49×	115.21×
−8.62×	−8.62×	—	−191.59×	−54.09×
4.56×	2.92×	0.00×	−1.22×	−17.66×
1.49×	1.49×	0.00×	0.42×	0.84×
−0.38×	−0.38×	−0.44×	−0.08×	−0.20×
2.16×	2.16×	2.19×	−0.69×	−1.05×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TAKE₹11.06

TAKE Limited

· Pharma & Health

₹ CrorePeersVIMTALABS SUVENMcap ₹164 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	3.13	11.74	—	0.00	0.00
Receivable Days (DSO)	57.99	103.16	—	0.73	0.73
Payable Days (DPO)	115.21	306.49	—	9.35	9.35
Cash Conversion Cycle (days)	-54.09	-191.59	—	-8.62	-8.62
Working Capital Turnover	-17.66	-1.22	0.00	2.92	4.56
Asset Turnover	0.84	0.42	0.00	1.49	1.49
Cash Conversion (CFO/Net Income)	-0.20	-0.08	-0.44	-0.38	-0.38
CFO/EBITDA	-1.05	-0.69	2.19	2.16	2.16

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.